Surrozen, Inc./DE (SRZN) income statement
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$31.74+1.76 (+5.87%)
Close on Nov 18, 2026Market cap $373.06MP/E –Yield –
Surrozen, Inc./DE income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -385.3%
- Net margin
- -2885.3%
- Return on equity, FY2025
- 231.4%
Financial strength
- Current ratio
- 12.14
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1132.4%
Valuation
- P/E ratio
- –
- Price to sales
- 32.41
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?